Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?

Literature DB >> 19010878

Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?

Abstract

Therapies targeting transforming growth factor beta (TGFbeta) signaling using neutralizing antibodies and small molecular inhibitors are in multiple clinical trails. However, TGFbeta is known to work as both a tumor suppressor and a tumor promoter, and current knowledge does not provide sufficient information on what factors mediate this switch in function and when this switch occurs. Recent advances in multiple disciplines suggest that immune cells from the tumor host may provide the answer.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 19010878 PMCID： PMC2741321 DOI： 10.1158/0008-5472.CAN-08-2556

Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701

35 in total

1. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors: T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal: N Engl J Med Date: 2001-04-19 Impact factor: 91.245

2. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.

Authors: Elizabeth Forrester; Anna Chytil; Brian Bierie; Mary Aakre; Agnieszka E Gorska; Ali-Reza Sharif-Afshar; William J Muller; Harold L Moses
Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701

3. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

Authors: Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin
Journal: Cancer Cell Date: 2004-10 Impact factor: 31.743

4. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation.

Authors: Shi-Long Lu; Douglas Reh; Allen G Li; Jennifer Woods; Christopher L Corless; Molly Kulesz-Martin; Xiao-Jing Wang
Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701

5. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Authors: Jeong-Seok Nam; Masaki Terabe; Mi-Jin Kang; Helen Chae; Nga Voong; Yu-An Yang; Arian Laurence; Aleksandra Michalowska; Mizuko Mamura; Scott Lonning; Jay A Berzofsky; Lalage M Wakefield
Journal: Cancer Res Date: 2008-05-15 Impact factor: 12.701

6. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation.

Authors: Giovanni Monteleone; Jelena Mann; Ivan Monteleone; Piero Vavassori; Ronald Bremner; Massimo Fantini; Giovanna Del Vecchio Blanco; Roberto Tersigni; Luciano Alessandroni; Derek Mann; Francesco Pallone; Thomas T MacDonald
Journal: J Biol Chem Date: 2003-11-04 Impact factor: 5.157

Review 7. Stromal fibroblasts in cancer initiation and progression.

Authors: Neil A Bhowmick; Eric G Neilson; Harold L Moses
Journal: Nature Date: 2004-11-18 Impact factor: 49.962

8. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors: François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal: J Exp Med Date: 2005-09-26 Impact factor: 14.307

9. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors: François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal: J Exp Med Date: 2005-10-17 Impact factor: 14.307

10. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors: Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal: J Exp Med Date: 2003-12-01 Impact factor: 14.307

57 in total

Review 1. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors: Li Yang; Yanli Pang; Harold L Moses
Journal: Trends Immunol Date: 2010-06-01 Impact factor: 16.687

Review 2. Smad linker region phosphorylation in the regulation of extracellular matrix synthesis.

Authors: Micah L Burch; Wenhua Zheng; Peter J Little
Journal: Cell Mol Life Sci Date: 2010-09-04 Impact factor: 9.261

3. Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.

Authors: Horatiu C Dancea; Mohammed M Shareef; Mansoor M Ahmed
Journal: Mol Cell Pharmacol Date: 2009

Review 4. Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders.

Authors: Stephen L Nishimura
Journal: Am J Pathol Date: 2009-09-03 Impact factor: 4.307

5. Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.

Authors: Ming-Yii Huang; Chih-Hung Lin; Chun-Ming Huang; Hsiang-Lin Tsai; Ching-Wen Huang; Yung-Sung Yeh; Chee-Yin Chai; Jaw-Yuan Wang
Journal: World J Surg Date: 2015-05 Impact factor: 3.352

6. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Authors: Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger
Journal: Clin Cancer Res Date: 2016-10-10 Impact factor: 12.531

10. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor.

Authors: Antonia Patsialou; Jeffrey Wyckoff; Yarong Wang; Sumanta Goswami; E Richard Stanley; John S Condeelis
Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701